Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Revenue (2016 - 2025)

Altimmune (ALT) has disclosed Revenue for 16 consecutive years, with $5000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Revenue changed 0.0% to $5000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $20000.0, a 61.54% decrease, with the full-year FY2024 number at $20000.0, down 95.31% from a year prior.
  • Revenue was $5000.0 for Q3 2025 at Altimmune, roughly flat from $5000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $3.3 million in Q4 2021 to a low of $2000.0 in Q3 2022.
  • A 5-year average of $259947.4 and a median of $8000.0 in 2022 define the central range for Revenue.
  • Peak YoY movement for Revenue: crashed 99.21% in 2022, then skyrocketed 18000.0% in 2023.
  • Altimmune's Revenue stood at $3.3 million in 2021, then tumbled by 99.21% to $26000.0 in 2022, then surged by 42.31% to $37000.0 in 2023, then tumbled by 86.49% to $5000.0 in 2024, then changed by 0.0% to $5000.0 in 2025.
  • Per Business Quant, the three most recent readings for ALT's Revenue are $5000.0 (Q3 2025), $5000.0 (Q2 2025), and $5000.0 (Q1 2025).